Cargando…

Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome

Women with polycystic ovary syndrome (PCOS) have an adverse metabolic profile with an increased risk of prediabetes and type 2 diabetes (T2DM); however, it is unclear if PCOS is associated with increased cardiovascular events in later years independent of the presence of T2DM. Many therapies have be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alalami, Huda, Sathyapalan, Thozhukat, Atkin, Stephen L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378434/ https://www.ncbi.nlm.nih.gov/pubmed/30800265 http://dx.doi.org/10.1177/2042018818805674

Ejemplares similares

Pharmacological Treatment of Obesity in Patients with Polycystic Ovary Syndrome
por: Kahal, Hassan, et al.
Publicado: (2011)

Mediators of Inflammation in Polycystic Ovary Syndrome in Relation to Adiposity
por: Sathyapalan, Thozhukat, et al.
Publicado: (2010)

A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome
por: Abdalla, Mohammed Altigani, et al.
Publicado: (2020)

Components of the Complement Cascade Differ in Polycystic Ovary Syndrome
por: Butler, Alexandra E., et al.
Publicado: (2022)

The Effect of Exenatide on Cardiovascular Risk Markers in Women With Polycystic Ovary Syndrome
por: Dawson, Alison J., et al.
Publicado: (2019)

ODP141 Complement Activation and Homeostasis Works Primarily Through the Alternative Pathway in Polycystic Ovary Syndrome
por: Atkin, Stephen, et al.
Publicado: (2022)

COVID-19 biomarkers for severity mapped to polycystic ovary syndrome
por: Moin, Abu Saleh Md, et al.
Publicado: (2020)

The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome
por: Sathyapalan, Thozhukat, et al.
Publicado: (2017)

Pregnancy in polycystic ovary syndrome
por: Kamalanathan, Sadishkumar, et al.
Publicado: (2013)

Correction to: COVID-19 biomarkers for severity mapped to polycystic ovary syndrome
por: Moin, Abu Saleh Md, et al.
Publicado: (2021)

Complement Dysregulation in Obese Versus Nonobese Polycystic Ovary Syndrome Patients
por: Butler, Alexandra E., et al.
Publicado: (2023)

The Association of the Polychlorinated Biphenyl Class of Endocrine Disruptors With Polycystic Ovary Syndrome and Thyroid Dysfunction
por: Brennan, Edwina, et al.
Publicado: (2021)

The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence
por: Abdalla, Mohammed Altigani, et al.
Publicado: (2021)

Salivary testosterone measurement in women with and without polycystic ovary syndrome
por: Sathyapalan, Thozhukat, et al.
Publicado: (2017)

Metabolic consequences of obesity on the hypercoagulable state of polycystic ovary syndrome
por: Moin, Abu Saleh Md, et al.
Publicado: (2021)

Biomarkers of COVID-19 severity may not serve patients with polycystic ovary syndrome
por: Moin, Abu Saleh Md, et al.
Publicado: (2021)

The relationship of soluble neuropilin-1 to severe COVID-19 risk factors in polycystic ovary syndrome
por: Moin, Abu Saleh Md, et al.
Publicado: (2021)

Vitamin D association with coagulation factors in polycystic ovary syndrome is dependent upon body mass index
por: Moin, Abu Saleh Md, et al.
Publicado: (2021)

Salivary and serum androgens with anti-Müllerian hormone measurement for the diagnosis of polycystic ovary syndrome
por: Sathyapalan, Thozhukat, et al.
Publicado: (2018)

Renin-Angiotensin System overactivation in polycystic ovary syndrome, a risk for SARS-CoV-2 infection?
por: Moin, Abu Saleh Md, et al.
Publicado: (2020)

Vitamin D Association With Macrophage-Derived Cytokines in Polycystic Ovary Syndrome: An Enhanced Risk of COVID-19 Infection?
por: Moin, Abu Saleh Md, et al.
Publicado: (2021)

Inflammatory Markers in Non-Obese Women with Polycystic Ovary Syndrome Are Not Elevated and Show No Correlation with Vitamin D Metabolites
por: Moin, Abu Saleh Md, et al.
Publicado: (2022)

Serum polychlorinated biphenyl levels and circulating miRNAs in non-obese women with and without polycystic ovary syndrome
por: Brennan, Edwina, et al.
Publicado: (2023)

Oxidative Stress Markers and Heat Shock Proteins in Non-Obese Women with Polycystic Ovary Syndrome Are Not Elevated and Show No Correlation with Vitamin D
por: Nandakumar, Manjula, et al.
Publicado: (2023)

SAT366 Expression of Amyloid-related Proteins Associated With Dementia in Polycystic Ovary Syndrome Compared to a Control Population
por: Butler, Alexandra E, et al.
Publicado: (2023)

The Effect of Free Androgen Index on the Quality of Life of Women With Polycystic Ovary Syndrome: A Cross-Sectional Study
por: Abdalla, Mohammed Altigani, et al.
Publicado: (2021)

HDL-Associated Proteins in Subjects with Polycystic Ovary Syndrome: A Proteomic Study
por: Butler, Alexandra E., et al.
Publicado: (2023)

Exploration of the correlation of serum polychlorinated biphenyl levels with luteal phase hormonal parameters and infertility in women with or without polycystic ovary syndrome
por: Butler, Alexandra E., et al.
Publicado: (2023)

The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome
por: Javed, Zeeshan, et al.
Publicado: (2020)

Classical and alternate complement factor overexpression in non-obese weight matched women with polycystic ovary syndrome does not correlate with vitamin D
por: Moin, Abu Saleh Md, et al.
Publicado: (2022)

High density lipoprotein-associated proteins in non-obese women with and without polycystic ovary syndrome
por: Butler, Alexandra E., et al.
Publicado: (2023)

A Randomized, Controlled Trial of Vitamin D Supplementation on Cardiovascular Risk Factors, Hormones, and Liver Markers in Women with Polycystic Ovary Syndrome
por: Javed, Zeeshan, et al.
Publicado: (2019)

Androsterone glucuronide to dehydroepiandrosterone sulphate ratio is discriminatory for obese Caucasian women with polycystic ovary syndrome
por: Cho, Li-Wei, et al.
Publicado: (2017)

Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss
por: Dawson, Alison J., et al.
Publicado: (2017)

Effect of Moderate Aerobic Exercise on Complement Activation Pathways in Polycystic Ovary Syndrome Women
por: Ramanjaneya, Manjunath, et al.
Publicado: (2022)

The CD105:CD106 microparticle ratio is CD106 dominant in polycystic ovary syndrome compared to type 2 diabetes and healthy subjects
por: Al-Qaissi, Ahmed, et al.
Publicado: (2019)

Impact of metformin on the clinical and metabolic parameters of women with polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials
por: Abdalla, Mohammed Altigani, et al.
Publicado: (2022)

The Effect of Atorvastatin (and Subsequent Metformin) on Adipose Tissue Acylation-Stimulatory-Protein Concentration and Inflammatory Biomarkers in Overweight/Obese Women With Polycystic Ovary Syndrome
por: Sathyapalan, Thozhukat, et al.
Publicado: (2019)

Metabolic comparison of polycystic ovarian syndrome and control women in Middle Eastern and UK Caucasian populations
por: Butler, Alexandra E., et al.
Publicado: (2020)

Pharmacological Management of Obesity in Patients with Polycystic Ovary Syndrome
por: Kourtidou, Christodoula, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_melmmfpaa2880vjbhu4nv0m0ue